Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Stock Down 4.2 %

Shares of EVGN opened at $1.58 on Monday. The company has a market capitalization of $8.49 million, a P/E ratio of -0.42 and a beta of 1.43. Evogene has a twelve month low of $1.44 and a twelve month high of $10.40. The firm has a 50 day moving average of $2.42 and a 200 day moving average of $4.50.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). The company had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Institutional Trading of Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets lifted its position in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.